

The role of purified α -amylase from soil bacteria *versus* crude cell supernatant from medium against clinical biofilm-forming bacteria

Elamary R. Bahgat¹; Fawziah M. Albarakaty² and Wesam M. Salem^{1*}.

¹South Valley University, Faculty of Science, Botany and Microbiology Department, 83523 Qena, Egypt.

²Biology department (Microbiology), Faculty of Applied sciences (Girl Branch), Umm Al Qura University, Makkah AlMoukarramh.

Running Head: Antibiofilm activity of purified α -amylase from soil- bacteria.

^{1*}Corresponding author. Mailing address: South Valley University, Faculty of Science, Botany and Microbiology Department, 83523- Qena, Egypt.

Phone: +201013065777. Fax: +2096 5211 279.

e-mail: wesam.salem@svu.edu.eg

ABSTRACT

Bacterial biofilms have become a significant and growing threat to human life, nature, and environmental health. The aim of this study is to isolate amylase-producing bacteria from the terrestrial environment (soil) for investigating their general inhibition of some pathogenic human bacterial biofilm. A total of 75 amylase producing isolates were obtained by serial dilution and streaking method. Amylolytic activity of these isolates was screened by a starch agar plate method. Isolates were characterized by morphological and biochemical methods. The isolated *Bacillus* species were *B. megaterium* (26.7%), *B. subtilis* (16%), *B. cereus* (13.3%), *B. thuringiensis* (10.7%), *B. lentus* (10.7%), *B. mycoides* (5.3%), *B. alvei* (5.3%), *B. polymyxa* (4%), *B. circulans* (4%) and *Micrococcus roseus* (4%). The optimum conditions for amylase production were monitored. Antagonistic activity of these isolates and purified amylase against multidrug-resistant pathogenic human bacteria by agar disk diffusion method. The sensitivity level of some standard antibiotics served as control. Interestingly, it was found that all isolates exhibited great antagonistic activity against the target pathogens. The greatest activity recorded by *B. alvei* (48 mm) against *Staphylococcus aureus* (MRSA) and the lowest activity recorded by *B. polymyxa* (12 mm) against *E. coli* while low inhibition recorded for amylase. Antibiofilm efficacy of isolates supernatant and purified enzyme also monitored by spectrophotometric methods. The results revealed highly significant inhibition with percentages of 93.6 and 78.8% respectively. So, they represent a good tool for biofilm control in clinical and environmental applications.

Keywords: Amylase, *Bacillus*, Soil bacteria, Antibiofilm, Pathogenic bacteria.

INTRODUCTION.

Bacterial biofilms have become a significant and growing threat to human life, nature, and environmental health [1]. This is due to its association with a variety of infectious diseases also, they are infectious in nature and can result in nosocomial infections [2]. Biofilms also showing high resistance to different antibiotics [3]. The first step in biofilm formation is the initial attachment to surfaces [4]. In a study by [5], he was found that extracellular polymers and gas production of bacteria involved in sloughing biofilm from surfaces. Using enzymes also is a good strategy for biofilm removal, as enzymes are rapidly biodegradable and

harmless to the environment [6]. Amylase is one member of digestive enzymes that hydrolyzes glycosidic bonds of starch to form maltotriose glucose, dextrin, and maltose so, it termed as glycosidic hydrolases [7]. Production of amylase by microbes is more advantageous due to the high production rate and can easily engineer into desired products [8]. Soil is the main part of the terrestrial environment that occupied with a large association of microorganisms compared with aquatic environments. This is due to its higher content of organic and inorganic materials [9]. Among terrestrial bacteria, *Bacillus* sp. that is a good choice of the source as amylase producers such as *Bacillus subtilis*, *Bacillus cereus* and *Bacillus polymyxa* [10,11]. Amylase from *Bacillus* is thermostable, has retention to extreme pH, osmolarity and high pressure and this is important in industrial production [12]. Antibiotics such as bacitracin, gramicidin S, polymyxin and tyrotridicin produced by *Bacillus* sp. exhibited great efficacy against Gram-positive and Gram-negative bacteria [13-15]. In this study, *Bacillus* sp. was isolated from soil, identified by morphological and biochemical assays. Antimicrobial activity of these isolates was investigated against five human pathogenic strains. Purification of amylase was done after its optimization and studying the best condition of temperature, pH, incubation period and starch concentration that gives the highest activity for purification. Finally, the antibiofilm activity of the isolates supernatant and the purified amylase from these isolates were monitored.

MATERIALS AND METHODS.

1- Soil samples collection. One hundred soil samples were collected from different places during November 2018 from the Luxor governorate, Egypt. Samples were collected in sterile plastic bags under aseptic conditions and transported to the laboratory [16]. One gram of soli added to 5 ml tryptic soy broth (Oxoid) modified with 1% starch as enrichment broth. Samples incubated at 37°C for 24h.

2- Screening and isolation of amylase-producing bacteria. Serial dilution techniques are one of the most precise methods for bacterial isolation from soil [17,18]. Serial dilutions were done up to 10^{-7} . 100 μ l from each dilution was transferred aseptically and spread into tryptic soy agar media fortified with 1% starch. The plates were incubated at 37°C for 24h and CFU/ml was determined. The plates were then flooded with iodine that turns blue when reacting with starch that not hydrolyzed. If starch is hydrolyzed, a clear halo zone was observed around colonies that produce amylase against a dark blue background [19,20]. Bacterial isolates were further subcultured to obtain a pure culture. Isolates were identified by standard morphological techniques based on colony shape, Gram's staining, spore formation and biochemical characterization [21-23]. Isolates were then maintained in 70% sterilized glycerol stock under -70 °C for further use.

3- Selection of isolates for amylase purification. The selection of isolates for extraction and purification of amylase, for studying the antibiofilm activity of the purified amylase against some human pathogenic bacteria, occurred according to starch hydrolysis ratio (SHR) that calculated from the following equation [24].

$$\text{SHR} = \text{clear halo zone diameter (mm)} / \text{colony growth diameter (mm)}.$$

Where isolates were subcultured on starch agar plates. Then the plates were incubated for 24h at 37°C. After incubation, the plates flooded with iodine. Finally, SHR was calculated according to the above equation.

4- Optimization of amylase production.

a- Effect of temperature and incubation periods. The starch nutrient medium was prepared and the pH adjusted to 7.5. The medium inoculated with the tested isolates. The cultured allowed to grow on a rotatory shaker (250 revs/min) at different temperatures ranged from 25 to 55°C for 48h. Then, 20 ml of each culture for all temperatures at different time

intervals (18, 24 and 48h) was taken and centrifuged to remove the bacterial cells. Finally, the supernatant was collected for assaying amylase activity [25].

b- Effect of pH. The starch nutrient medium was prepared and pH was adjusted to different values from 5 to 10. Each isolate was inoculated into a set of this medium and grown at 50°C for 24h. Then, 20 ml of each were collected and treated as above for determination amylase activity [25].

c- Effect of starch concentration. *Bacillus* isolates were grown on nutrient broth medium at pH 9 except *Bacillus subtilis* at grown at pH 7. Fresh medium was prepared with the addition of different soluble starch quantities to give a final concentration of 0.1, 0.5, 1, 1.5, 2, 2.5 and 3%. Then isolates were inoculated each in a set of this medium and grown at 50°C for 24h. Finally, amylase activity was determined [25].

5- Determination of amylase activity under optimum conditions. The assay mixture containing 2 ml of a solution of 1% starch in 50 mM sodium phosphate buffer (pH7) and 0.1 ml enzyme solution. After 10 min. of incubation at 40°C, the reaction was stopped by adding 2 ml of 3,5 dinitrosalicylic acid (DNS) reagent and the tubes were heated at 100°C for 5 minutes. The absorbance was measured spectrophotometrically at 540 nm against a blank containing buffer instead of the culture supernatant. The amount of reducing sugars was calculated from a standard curve constructed by using maltose [26]. Protein was determined using the method of [27].

6- Enzyme purification.

a- Ammonium sulfate precipitation. The crude amylase enzyme was brought to 45% saturation with ammonium sulfate and kept overnight in a cold room at 4°C. The precipitate was discarded, while the supernatant was brought to 85% saturation with ammonium sulfate and centrifuged at 8000 rpm at 4°C for 10 min. The precipitate from this step was collected and stored at 4°C. [28].

b- Dialysis. This step was conducted to exclude the remains of ammonium sulfate and concentrate the enzyme. The dialysis tubes, which were previously soaked in 0.1 M phosphate buffer, pH 6.2 were used for dialysis of the precipitate. The precipitate was dissolved in 0.1 M phosphate buffer and dialyzed against the same buffer [29].

c- DEAE sephadex A-25. The crude enzyme preparations of the six culture filtrate were applied separately to a column of DEAE-Sephadex A-25. The enzyme was eluted with a linear gradient of sodium chloride (0 – 0.4 M) in 200 ml of sodium phosphate buffer (0.05 M and pH 7), the flow rate was adjusted to 1 ml per 1 min. and the 200 ml of eluents were collected into 40 tubes (1x7 cm) using an automatic circular fraction collector. Enzyme activity and protein concentration were determined in each fraction as described in the assay method. Fractions of the highest specific activity were pooled together and kept for further studies.

7- Antibacterial activities.

7.1. Antagonistic efficacy of the isolated bacteria. The antagonistic efficacy of all isolates was studied against 5 human pathogenic strains. The used pathogenic strains in the study work (*Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Staphylococcus aureus* (MRSA)) were kindly obtained from the International Luxor hospital in Luxor province, Egypt. The screening was done by disc diffusion method. All bacteria were cultured on TSB modified with 1% starch and incubated at 37°C at 24h. The isolated bacterial cultures were centrifuged to exclude the cell debris (6000 rpm – 15 min. - Biofuge). Then 20 ml of TSA modified with 1% starch was poured in a sterile Petri plate (100 mm diameter). 100 µl of 5 tested pathogens were streaked on the plates and by using sterile borer, wells of 6 mm were punched in the plates. The wells were then filled with 100 µl of the isolated bacteria supernatant. The plates were then incubated at 37°C for 24h. The inhibition zone was measured using a ruler in mm [30]. Standard antibiotics were served as

control using Kirby Bauer disk diffusion method [31]. The used antibiotics were Chloramphenicol (C; 30 µg, Oxoid), Oxacillin (OX; 1 mcg, Bioanalyse®), Vancomycin (VA; 30 mcg, Bioanalyse®), Ampicillin/Sulbactam (SAM; 10/10 mcg, Bioanalyse®), Penicillin G (P; 10 U; Bioanalyse®), Erythromycin (E; 15 mcg, Bioanalyse®), Sulfamethoxazole/Trimethoprim (SXT; 23.75/1.25 µg, BBL™), Cefotaxime (CTX; 30 mcg, Bioanalyse®), Gentamycin (GM; 10 µg, Bioanalyse®), Meropenem (MEM; 10µg, Bioanalyse®), Piperacillin (PIP; 100 µg, Bioanalyse®) and Piperacillin-tazobactam (PTZ; 100/10 µg, Bioanalyse®). Interpretation of the results was done according to Clinical Laboratory Standard Institute guidelines [32] to determine if the tested pathogens were resistant, intermediate or sensitive against the used antibiotics.

7.2. Antibacterial activity of purified amylase enzyme from the selected isolated *Bacillus*. 100 µl of purified amylase from the selected isolates according to SHR were put in the wells of the agar plates inoculated with the target strains as described earlier. The plates then incubated at 37°C for 24h. The diameter of the halo zone was measured using a ruler expressed in mm.

7.3. Biofilm formation assay. The ability of the tested pathogens: *E. coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* (MRSA) for biofilm formation was determined using 96-well polystyrene plates [33] after modifications by [34] as follows: isolates were subcultured on tryptic soy agar for 24h at 37°C, suspended in tryptic soy broth and adjusted to an OD₅₉₅ of 0.02. 130 µl of each adjusted isolate culture were put in the microtitre plate (U bottom, Sterilin) at 37°C for 48h. After incubation the wells were washed with distilled water (6 times), Furthermore, the wells were stained with 0.1% crystal violet for 10 min. the wells were again washed with distilled water (4 times) to remove excess stain. Finally, the wells were destained by 210 µl of ethanol

96% and the OD₅₉₅ was read using infinite[®] F50 Robotic (Ostrich) Microplate Plate to quantify the amount of biofilm.

7.4. Antibiofilm activity of the isolated *Bacillus sp.* supernatant and its purified amylase enzyme. The effect of the isolated bacteria supernatant and purified amylase of selected isolates as antibiofilm against five human biofilm former pathogenic bacteria were done by spectrophotometric methods as follows: a fresh culture of the isolates was prepared and adjusted to 0.5 McFarland (10⁶ CFU/ml). 30 µl (This volume was selected according to preliminary experiment) of these cultures and purified amylase enzyme was added to 130 µl the tested pathogens at OD₅₉₅ of 0.02 after 24h incubation for allowing biofilm formation. The plates then incubated for 48h and then stained with crystal violet as described earlier. Wells without isolated cultures or amylase served as control.

RESULTS.

1- Screening and isolation of amylase producing bacteria. After streaking of diluted soil samples that collected from Luxor, Egypt, on starch agar plates and flooding the plates with an iodine solution to observe the halo zone around some colonies that indicating amylase production, it was found that a total of seventy-five bacterial isolates were amylase producer. Bacterial isolates were selected according to their amylolytic activity (Fig.1). Isolates were further characterized by morphological and biochemical tests as shown in Table (1 and 2). The results showed that the seventy-five isolates were 19 *B. megaterium*, 12 *B. subtilis*, 10 *B. cereus*, 8 *B. thuringiensis*, 8 *B. lentus*, 4 *B. mycoides*, 4 *B. alvei*, 3 *B. polymyxa*, 3 *B. circulans*, and 3 *Micrococcus roseus*. The highest prevalence recorded to *B. megaterium* (26.7%) and the lowest one was to *B. circulans* and *Micrococcus roseus* (4%). CFU of the amylase producing bacteria in one hundred soil samples ranged from 115x10³ – 198x10⁵ CFU/ml Table (1).

2- Optimization of amylase production. Starch hydrolysis rate as shown in (Table 2, Fig. 1d) lead to the selection of six isolates for amylase purification with the highest hydrolysis rate namely *B. alvei*, *B. thuringiensis*, *B. megaterium*, *B. subtilis*, *B. cereus*, and *B. lentus* with SHR of 6.0, 5.67, 5.33, 5.0, 4.0 and 3.5 mm respectively. The optimization was done to select the best conditions as temperature (25°C), the incubation period (24h), pH (8), and starch concentration (1.5-2%) that gives the highest amylase activity for using in purification (Fig. 2).

a- Effect of temperature and time intervals. All isolates showed maximum amylase production after 24h. *B. megaterium*, *B. subtilis*, and *B. cereus* showed maximum amylase production at 45°C while, other isolates showed maximum amylase production ranged from 25- 30°C (Fig. 2 a and b).

b- Effect of pH. All *Bacillus* isolates give maximum amylase production at pH 8.0 except *B. subtilis* produced amylase maximally at pH 7.0 (Fig. 2c).

c- Effect of substrate concentration. The results showed that *B. subtilis* and *B. cereus* give maximum amylase production at 1.5 % of soluble starch. The remain isolates give maximum amylase production at 2.0 % of soluble starch (Fig. 2d).

d- Enzyme activity. As shown in Table (4), the highest amylase activity produced by *B. alvei* (96.02 U/ml) followed by *B. thuringiensis* (88.64 U/ml). While, *B. megaterium*, *B. subtilis* and *B. cereus* produced amylase activity of 80.03, 76.0 and 55.9 U/ ml respectively. On the other hand, *B. lentus* produced the lowest amylase activity of 45.69 U/ml.

3- Antibacterial activity.

3.1. Antagonistic efficacy of the isolated bacteria and purified amylase enzyme from selected isolates. This study established the antimicrobial activity of the isolated amylase producing bacteria and purified amylase against five human pathogenic bacteria, the sensitivity level of some standard antibiotics served as a control, the results were shown in

(Table 3; Fig. 1, a-b and c). It was found that *E. coli* was resistant to sulfamethoxazole-trimethoprim, gentamycin, cefotaxime, piperacillin, and piperacillin-tazobactam. While it was intermediate to ampicillin-sulbactam and sensitive to chloramphenicol and meropenem. Interestingly, it was found that all isolated bacteria have better antimicrobial activity against *E.coli* with the highest effect recorded to *B. polymyxa* (36 mm) and the lowest effect recorded to *B. subtilis* and *B. cereus* (12 mm). On the other hand, *B. mycooides* and *M. roseus* had no antimicrobial activity against *E. coli* (Fig.1c). *K. pneumoniae* was resistant to all tested antibiotics while it was intermediate to ampicillin sulbactam. It is worth mentioning that, all isolates had great antimicrobial effects with the highest inhibition recorded to *B. megaterium* (26 mm) and the lowest effect recorded to *B. polymyxa* (17 mm) (Table 3). In contrast, *B. mycooides* and *M. roseus* were resistant to *K. pneumoniae* (Fig.1c). *A. baumannii* was resistant to all tested antibiotics and sensitive to only chloramphenicol. On the other hand, all isolated bacteria had better antibacterial effects against tested pathogens with the greatest effect was to *B. alvei* and *B. cirulans* (39 mm) and the lowest effect was to *B. subtilis* and *B. thuringiensis* (21 mm) (Table 3). Although, no inhibitory effect recorded to *B. mycooides* and *Micrococcus roseus* against the tested pathogens (Fig.1c). The susceptibility level of *P. aeruginosa* indicated that it was resistant to sulfamethoxazole-trimethoprim, cefotaxime, gentamycin, meropenem and piperacillin. But it was intermediate to chloramphenicol and ampicillin-sulbactam, sensitive to piperacillin-tazobactam. It is important to say that all isolates had a great antibacterial effect against tested pathogens with the highest effect recorded to *B. lentus* and *B. cirulans* (32 mm) and the lowest on to *B. subtilis* (15 mm). Finally, *S. aureus* (MRSA) was resistant to oxacillin, vancomycin, penicillin G, cefotaxime and Gentamycin while, it was intermediate to chloramphenicol, erythromycin, and sulfamethoxazole-trimethoprim. On the other hand, the isolated amylase producing bacteria had a better antibacterial effect on tested pathogens with the greatest effect recorded to *B. alvei* (48 mm) and the lowest effect

recorded to *B. cereus* (14 mm) (Table 3). but *B. mycoides* and *M. roseus* had no effect *S. aureus* (Fig.1c). Antibacterial activity of purified amylase from selected isolates showed very little effect on *E. coli* and *K. pneumoniae* (The highest inhibition diameter was 7.5 mm) but no effect recorded against the other tested pathogens (Table 3).

3.2. Antibiofilm activity of isolated bacterial supernatant and purified amylase enzyme

from selected *Bacillus* isolates. The ability of pathogenic bacterial strains for biofilm formation by spectrophotometric methods was confirmed before the antibiofilm treatments with bacterial supernatant and purified amylase enzyme. As shown in Fig. (3 and 4), the antibiofilm activity was screened by the spectrophotometric method using crystal violet staining. Our results showed that *B. megaterium* inhibits biofilm of *E. coli*, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa*, *Staphylococcus aureus* (MRSA) significantly with percentages of 63.3, 91.8, 73.2, 27.9 and 52.7% respectively (Fig. 3 T1). The second isolate was *B. subtilis*, this isolate also recorded high significant effect in biofilm inhibition with percentages of 74, 93, 73.7, 54 and 61.9% after 48h of treatment for *E. coli*, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa* and *S. aureus* (MRSA), respectively (Fig. 3 T2). Antibiofilm activity of *B. cereus* showed significant inhibition percentages of 64.5, 92.6, 61.1, 21.6 and 58.6% after 48h treatment of the tested pathogens respectively (Fig. 3 T3). The efficacy of *B. thuringiensis* also has been monitored, the results revealed high significant inhibition of biofilm with percentages of 39.6, 92, 74.3, 50.8 and 66.3% respectively (Fig. 3 T4). *B. lentus* recorded high significant inhibition biofilm with percentages of 66, 90.8, 74.5, 52.8 and 73.3% (Fig. 3 T5). *B. alvei* showed also highly significant inhibition with the percentage of 31.9, 68.7, 74, 56.3, 81.6% (Fig. 3 T6). *B. polymyxa* and *B. circulans* also have great efficacy as antibiofilm against *E. coli*, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa* and *S. aureus* (MRSA) with percentage of (68.9, 92.8, 72.6, 56.7, 70.9%) and (49, 93.7, 71.4, 28.2, 77.3 %) respectively after 48h treatment Fig. (3 T7 and T8). Efficacy of purified amylase enzyme as antibiofilm

also had been monitored against the same tested pathogens. Results revealed that maximum activity was recorded by *B. alvei* (enzyme activity, 96.02 U/ ml) with significant inhibition percentages of 74, 78.8, 78.2, 76.2 and 74.5%, respectively (Fig. 4 T6). *B. thuringiensis* (enzyme activity, 88.64 U/ ml) comes after *B. alvei* as antibiofilm with percentages of 69.7, 75, 74.1, 68 and 69.5% on *E. coli*, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa* and *S.aureus* (MRSA), respectively (Fig. 4 T4). *B. megaterium* (enzyme activity, 80.03 U/ ml) and *B. subtilis* (enzyme activity, 76.0 U/ml) comes after *B. alvei* and *B. thuringiensis* inefficacy of biofilm inhibition with percentages of (65.6, 71, 71.6, 61.6, 64.3%) and (62.4, 67.8, 70, 50, 61.5%) respectively after 48h of treatment (Fig 4 T1 and T2). The lowest efficacy as antibiofilm recorded to *B. cereus* (enzyme activity, 55.9 U/ml) and *B. lentus* (enzyme activity, 45.69 U/ml) where after 48h treatment biofilm of the tested pathogens decrease by (55, 66.7, 68, 46.4 and 59 %) and (41.3, 60.6, 62, 32.4 and 53.7%) respectively Fig. (4 T3 and T5).

Statistical analysis. Data were analyzed using the Mann-Whitney U test or a Kruskal-Wallis test followed by post hoc Dunn's multiple comparisons. Differences were considered significant at P values of ≤ 0.05 . For all statistical analyses, GraphPad Prism version 5 was used.

DISCUSSION.

Since pathogenic bacteria became extremely resistant to generally used antibiotics. In addition, the unused antibiotics may dispose in the sewage system and if they are not depredated during sewage treatment in the soil they may reach ground, surface and drinking water. This will be a great fate and risk entering the environment [35]. Searching for new natural antimicrobial became important requirements for pharmaceutical industries to overcome the problem of multidrug-resistant strains [36]. Antibiotic production is a feature of

several soil organisms that represents a survival mechanism by which organisms can eliminate competition [37,38]. Genus *Bacillus* is among terrestrial strains that have the ability to produce inhibitory compounds from peptide derivative and lipopolypeptides antibiotics [39-41]. Our study based on isolation of amylase producing- bacteria from soil and the results of isolation indicated that *Bacillus* species were obtained by 96% from the total number of isolates (Table. 1, 2). [15,42], found that isolated bacteriocin producing strains such as *Bacillus* sp. were active against Gram-negative and Gram-positive bacteria. [13,43], displayed that *B. subtilis*, *B. thuringiensis* and *B. megaterium* have antibacterial activity against *E. coli* and *Pseudomonas aeruginosa*. Our study confirmed the antibacterial activity of the isolated *Bacillus* sp. (*B. megaterium*, *B. cereus*, *B. subtilis*, *B. thuringiensis*, *B. lentus*, *B. alvei*, *B. polymyxa* and *B. circulans*) against multidrug-resistant human pathogenic strains (*E. coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *S. aureus* (MRSA) that confirmed by our results on standard antibiotics (Table. 3). The results revealed that 80% of the isolated species have inhibitory effect against the tested pathogens as shown in Table (3) Fig 1 (a and b). On the other hand, results revealed that purified amylase enzyme obtained from these isolates has a very little antibacterial effect against *E. coli* and *K. pneumoniae* while no effect verified against *A. baumannii*, *P. aeruginosa* and *S. aureus* (MRSA) (Table 3; Fig. 1c) in agreement with [44] who confirmed that amylase enzyme has no antibacterial effect. Bacterial biofilm is considered a great threat to human life because of its antibiotic resistance [4, 45]. Also it contributes to the chronicity of infections [46]. Our results revealed highly significant inhibition of biofilm produced by *E. coli*, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa* and *S. aureus* (MRSA) using some isolated *Bacillus* species extracellular metabolites (supernatant) Fig. (3) . The results showed greatest inhibition obtained by *B. circulans* against *K. pneumoniae* biofilm with percentage of 93.6% and the lowest inhibition recorded by *B. cereus* against *P. aeruginosa* biofilm with

percentage of 21.7%. This may be due to presence of some extracellular and intracellular metabolites in the medium where intracellular can release into extracellular medium when accumulated in the cell and this has been explained by the metabolic overflow theory [47-49]. *Bacillus* also has great efficacy for production of carbohydrate-active enzymes, bioactive compounds, secretion of a variety of extracellular metabolites and lytic enzymes [50]. Where, *Bacillus* species are the most popular producing peptide antibiotic compounds such as polymyxin, colistin, and circulin [51,52].

Antimicrobials are unable to penetrate biofilm due to the presence of extracellular polymeric substances (EPS) that considered a primary matrix of biofilm [53]. It produced by bacteria that bind with surfaces for some periods [6]. So, this layer plays an important role in facilitating bacterial attachment [54] Capture nutrients [55] also stabilizer of the biofilm structure and protecting the barrier of bacteria inside biofilm [56] EPS is highly hydrated because it incorporated a large amount of water into its surface by hydrogen bonding [57]. So, treatment of biofilm depends on removal of EPS. Enzymes are playing important role in removing and inactivation of bacterial biofilm [58-60]. So, significant reduction of biofilm for *E. coli*, *K. pneumoniae*, *A.baumannii*, *P. aeruginosa*, and *S. aureus* (MRSA) that revealed by our results due to using purified amylase enzyme of selected *Bacillus* isolates may be due to the above-mentioned explanations Fig. (4). The greatest inhibition recorded to amylase of *B. alvei* against *K. pneumoniae* with percentage of 78.8% and the lowest effect was to amylase of *B. lentus* against *P. aeruginosa* with percentages of 20.6%. Results also indicated a great inhibition of biofilm obtained amylase enzyme of *B. alvei* followed by *B. thuringiensis*, *B. megaterium*, *B. subtilis*, *B. cereus* and *B. lentus*. This may be due to the increased enzyme activity of each of them. Where, enzyme activity was 96.02, 88.64, 80.03, 76.0, 55.9 and 45.69 U/ml respectively Table (4). It is worth mentioning that the supernatant

of isolated bacteria showed great antibiofilm activity compared with the purified amylase enzyme from the selected isolates.

CONCLUSION. In this study, for the first time, supernatant of different isolated *Bacillus sp.* (amylase producer) from the soil, was found to be an excellent antibiofilm agent against five human pathogenic biofilm former strains. The highest inhibition percentage was 93.6 %. Antibiofilm activity of purified amylase also monitored with inhibition percentages of 78.8%. Hence, our study was evidence that the supernatant of *Bacillus* was a good antibiofilm in clinical applications. Further studies are in progress to identify the exact composition of the supernatant and its active compounds.

REFERENCES.

1. Hall-Stoodley, L.; Costerton, J.W.; Stoodley, P.. Bacterial biofilms: from the natural environment to infectious diseases. *Nature Reviews Microbiology*. 2004, 2, 95–108.
2. Jamal, M.; Tasneem, U.; Hussain, T.; Andleeb, S. Bacterial Biofilm: Its Composition, Formation and Role in Human Infections. *Research & Reviews: Journal of Microbiology and Biotechnology*. 2015, 4 (3), 1-14.
3. Sharma, D.; Misba, L.; Khan. A.U. Antibiotics versus biofilm: an emerging battleground in microbial communities. *Antimicrobial Resistance and Infection Control*, 2019, 8,76.
4. Costerton J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial biofilms: a common cause of persistent infections. *Sci*. 1999, 284, 1318-1322.
5. Bryers, J.D. 'Modelling biofilm accumulation', in M.J. Bazin and J.1.Prosser (eds.), *Physiological Models in Microbiology*. CRC Press, Boca Raton. 1988, 109-144.

6. Xavier, J.B.; Piciooreanu, C.; Rani, S.A.; van Loosdrecht, M.C.M.; Stewart, P.S. Biofilm control strategies based on enzymatic disruption of the extracellular polymeric substance matrix- a modeling study. *Microbiol.* 2005, *51*, 3817-3832.
7. Kaur, A.; Kaur, M.; Samyal, M.L.; Ahmed, Z. Isolation, characterization and identification of bacterial strain producing amylase. *J. Microbiol. Biotech. Res.* 2012, *2* (4), 573-579.
8. Lonsane, B.K.; Ramesh, M.V. Production of Bacterial Thermostable α -Amylase by Solid-State Fermentation: A Potential Tool for Achieving Economy in Enzyme Production and Starch Hydrolysis. *Advances in Appl. Microbiol.* 1990, *35*, 1-56.
9. Murphy, D.V.; Stockdale, E.A.; Brookes P.C.; Goulding, K.W.T. Impact of Microorganisms on Chemical Transformations in Soil. *Soil Biological Fertility.* 2007, 37-59.
10. El-Fallal, A.; Dohara, M.A.; El-Sayed, A.; Omar, N. Starch and Microbial α -Amylases: From Concepts to Biotechnological Applications. In Chang, *Carbohydrates - Comprehensive Studies on Glycobiology and Glycotechnology.* 2012, 459-476.
11. Dash, B.K.; Rahman, M.M.; Sarker, P.K. Molecular Identification of a Newly Isolated *Bacillus subtilis* BI19 and Optimization of Production Conditions for Enhanced Production of Extracellular Amylase. *Bio. Med. Res. Int.* 2015, 1-9.
12. Islam, T.; Choudury, N.; Hossain, M.M.; Khan, T.T. Isolation of Amylase Producing Bacteria from Soil, Identification by 16S rRNA Gene Sequencing and Characterization of Amylase. *Bangladesh J. Microbiol.* 2017, *34* (1), 01-06.
13. Perez, C.; Suarez, C.; Castro, G.R. Production of antimicrobials by *Bacillus subtilis* MIR 15. *J. Biotechnol.* 1992, *26*, 331-336.
14. Perez, C.; Suarez, C.; Castro, G.R. Antimicrobial activity determined in strains of *Bacillus circulans* cluster. *Folia Microbiol.* 1993, *38* (1), 25-28.

15. Yilmaza, M.; Sorana, H.; Beyatlib, Y. Antimicrobial activities of some *Bacillus* spp. strains isolated from the soil. *Microbiological Research*. 2006, *161*, 127- 131.
16. Reed, J.F.; Rigney, J.A. Soil sampling from fields of uniform and nonuniform appearance and soil types. *J. Ame. Soc. Agr.* 1947, *39*, 26-40.
17. Jamil, B.; Hasan, F.; Hameed, A.; Ahmed, S. Isolation of *Bacillus subtilis* MH-4 from Soil and its Potential of Polypeptidic Antibiotic Production. *Pak. J. Pharm. Sci.* 20(1), 26-31. 9. Johnson T.R. laboratory Experiment in Microbiology (5th Edition), The Benjamin/Cummings Publishing co.inc. (1998), California. 2007.
18. Rasooli, I.; Astaneh, S.D.A.; Borna, H.; Barchini, K.A.A. Thermostable α -Amylase Producing Natural Variant of *Bacillus* spp. Isolated From Soil in Iran. *American Journal of Agricultural and Biological Sciences*. 2008, *3* (3), 591-596.
19. Gupta, R.; Gigras, P.; Mohapatra, H.; Goswami, V.K.; Chauhan, B. Microbial-amylases: A Biotechnological perspective. *Process Biochem.* 2003, *38*, 1599-1616.
20. Abd-Elhahlem, B.T.; El-Saway, M.; Gamal, R.F.; Abou-Taleb, K.A. Production of amylases from *Bacillus amyloliquefaciens* under submerged fermentation using some agro industrial by-products. *Ann. Agr. Sci.* 2015, *60* (2), 193–202.
21. Cruickshank, R.; Duguid, J.; Marmion, B.; Swain, R. Medical Microbiology 12th, ed., Edinburg, London and New York. 1975.
22. Collins, C.; Lyne, P. Microbiological methods 5th microbiology laboratory manual, British Librery. Butter Worth, Inc., United Kingdom. 1984.
23. Koneman, E., Allen, S., Janda,W., Schrenchen, P., Winn, W. Color atlas and Text book of Diagnostic Microbiolog. 4th Ed. Published by L.B Lippincott Company, Philadelphia, USA. 1992.

24. Pranay, K.; Padmadeo, S.R.; Jha, V.; Prasad, B. Screening and identification of amylase producing strains of *Bacillus*. *Journal of Applied Biology & Biotechnology*. 2019, 0(00), 1-6.
25. Nimisha, P.; Moksha, S.; Gangawane, A.K. Amylase Activity of Starch Degrading Bacteria Isolated from Soil. *Int. J. Curr. Microbiol. App. Sci.* 2019, 8(4), 659-671.
26. Meyer, K.H.; Fisher, E.H.; Bernfeld, P. In: "General Biochemistry". Fritton, S. S. and Simmonds, S. (eds.) (1951). 2nd. ed. pp. 434-450. J. Wiley, New York. 1951.
27. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein -dye binding. *Analytical Biochemistry*. 1976, 72, 248-254.
28. Analytical biochemistry & separation techniques by Dr. P. Palamivelu, School of Biotechnology, Madurai University.
29. Roe, S. Purification and Concentration by Precipitation. New York, NY, USA: Oxford University Press (S. Roe, Ed.). 2001.
30. Reinheimer, J.A.; Demkov, M.R.; Condioti, M.C. Inhibition of coliform bacteria by lactic cultures. *Aust. J. Dairy Technol.* May, 1990, 5-9.
31. Bauer, K.A.; Sherris, J.; Turk, M. Antibiotic susceptibility testing by standardized single disc method. *Am. J. Clin. Pathol.* 1966, 45, 493-496.
32. Clinical and Laboratory Standards Institute (CLSI), Document M100. Performance Standards for Susceptibility Testing: 27th ed., Clin. Lab. Stand. Inst, 2017. 37 (1), 282.
33. Seper, A.; Fengler, V. H.; Roier, S.; Wolinski, H.; Kohlwein, S. D.; Bishop, A. L.; Camilli, A.; Reidl, J. and Schild, S. Extracellular nucleases and extracellular DNA play important roles in *Vibrio cholerae* biofilm formation. *Mol. Microbiol.* 2011, 82, 1015-1037.

34. Salem, W.M.; Schneditz, G.; Dornisch, E.; Schild S. *In vitro* effects on biofilm viability, cytotoxicity and antibacterial activity of green Ag an ZnO nanoparticales against Nontypeable *Haemophilus influenza* strains, *JEAAS*. 2015,1, 369-383.
35. Kümmerer, K. Significance of antibiotics in the environment. *Journal of Antimicrobial Chemotherapy*. 2003, 52, 5–7.
36. Schmidt, F.R. The challenge of multidrug resistance: actual strategies in the development of novel antibacterials. 2004, 63(4), 335–343.
37. Talaro, A.; Talaro, K. Drugs, Microbes, Host. The Elements of Chemotherapy In Foundations in Microbiology. W.M. Brown: New York. 1996.
38. Jensen, M.J.; Wright., D.N., Chemotherapeutic Agents. *In: Microbiology for the Health Sciences: Prentice Hall, New York*. 1997, 132-145.
39. Mannanov, R.N.; Sattarova, R.K. Antibiotics produced by Bacillus bacteria. *Chem. Nat. Comp*. 2001, 37, 117-123.
40. Tamehiro, N.; Okamoto-Hosoya, Y.; Okamoto, S.; Ubukata, M.; Masa, Hamada, M.; Naganawa, H.; Ochi, K. Bacilysoicin, a novel phospholipid antibiotic produced by *Bacillus subtilis* 168. *Antimicrob. Agents Chemother*. 2002, 46, 315-320.
41. Stein, T. *Bacillus subtilis* antibiotics: structures, syntheses and specific functions. *Mol. Microbiol*. 2005, 56, 845-857.
42. Oscariz, J.C.; Lasa, I.; Pisabarro, A.G. Detection and characterization of cerein 7, a new bacteriocin produced by *Bacillus cereus* with a broad spectrum of activity. *FEMS Microbiol. Lett*. 1999, 178, 337–341.
43. Aslim, B.; Saglam, N.; Beyatli, Y. Determination of some properties of Bacillus isolated from soil. *Turk. J. Biol*. 2002, 26, 41–48.

44. Kalpana, B.J.; Aarthy, S.; Pandian, S.K. Antibiofilm Activity of α -Amylase from *Bacillus subtilis* S8-18 Against Biofilm Forming Human Bacterial Pathogens. *Appl. Biochem. Biotechnol.* 2012, *167*, 1778–1794.
45. Khan, S.; Singh, P.; Ansari, M.; Asthana, A. Isolation of *Shigella* species and their resistance patterns to a panel of fifteen antibiotics in mid and far western region of Nepal. *Asian Pacific J. Tropical Dis.* 2014, *4*, 30-34.
46. Stewart, P.S.; Costerton, J.W., Antibiotic resistance of bacteria in biofilms. *Review. The Lancet.* 2001, *358*, 135-138.
47. Pinu, F.R.; Villas-B^oas, S.G.; Aggio, R. Analysis of intracellular metabolites from microorganisms: quenching and extraction protocols. *Metabolites.* 2017, *7*, 53.
48. Pinu, F.R.; Granucci, N.; Daniell, J.; Han, T.-L.; Carneiro, S.; Rocha, I.; Nielsen, J.; Villas-B^oas, S.G. Metabolite secretion in microorganisms: the theory of metabolic overflow put to the test. *Metabolomics.* 2018, *14*, 43.
49. Horak, G.; Engelbrecht, P.J.; Rensburg, J.V.; Claassens, S. Microbial metabolomics: essential definitions and the importance of cultivation conditions for utilizing *Bacillus* species as bionematicides. *Journal of Applied Microbiology.* 2019, *127*, 326-343.
50. Abdel-Aziz, S.M. Extracellular Metabolites Produced by a Novel Strain, *Bacillus alvei* NRC-14: 5. Multiple Plant-Growth Promoting Properties. *J. Basic. Appl. Sci. Res.* 2013, *3(1)*, 670-682.
51. Katz, E.; Demain, A.L. The peptide antibiotics of *Bacillus*, chemistry, biogenesis, and possible functions. *Bacteriol. Rev.* 1997, *41*, 449-474.
52. Atanasova-Pancevska, N.; Popovska, I.; Davaliev, K., Kungulovski, D. Screening for Antimicrobial Activity of *Bacillus subtilis* and *Paenibacillus Alvei* Isolated From Rotten Apples Compost. *Acta Microbiologica Bulgarica.* 2016, 57-64.

53. Flemming, H.C.; Neu, T.R.; Wozniak, D.J. EPS matrix: The “House of Biofilm cells”. *Bacteriol.* 2007, *189*, 7945-7947.
54. Stoodley, L.H.; Stoodley, P. Developmental regulation of microbial biofilms. *Cur. Op. Biotechnol.* 2002, *13*, 228-233.
55. Gomez – Suarez, C.; van der Borden, P.J.; Wingender, J.; Flemming, H.C. Influence of extracellular polymeric substances deposition and redistribution of *Pseudomonas aeruginosa* to surface. *Microbiol.* 2002, *148*, 1161-1169.
56. Ploux, L.; Beckendorff, S.; Nardin, M.; Neunlist, S. Quantitative and morphological analysis of biofilms formation on self-assembled monolayers. *Col. Surf.* 2007, *57*, 174-181.
57. Prakash, B.; Veeregowda, B.M.; Krishnappa, G. Biofilms: A survival strategy of bacteria. *Cur. Sci.* 2003, *85*, 9-10.
58. Johansen, C.; Falholt, P.; Gram, L. Enzymatic removal and disinfection of bacterial biofilms. *Appl. Environ. Microbiol.* 1997, *63* (9), 3724–3728.
59. Molobela, P.; Cloete, T.E.; Beukes, M. Protease and amylase enzymes for biofilm removal and degradation of extracellular polymeric substances (EPS) produced by *Pseudomonas fluorescens* bacteria. *African Journal of Microbiology Research.* 2010, *4*(14), 1515-1524.
60. Lequette, Y.; Boelsb, G.; Clarissea, M.; Faille, C. Using enzymes to remove biofilms of bacterial isolates sampled in the food-industry. *Biofouling.* 2010, *26*, 421–431.

Table (1): Prevalence of *Bacillus* species isolated from soil

Isolates ^a	Parameters	No. of isolates ^b	Percentage ^c (%)	CFUml ^{-1d}
<i>Bacillus megaterium</i>		20	26.7	115×10 ³ – 198×10 ⁵
<i>Bacillus subtilis</i>		12	16	
<i>Bacillus cereus</i>		10	13.3	
<i>Bacillus thuringiensis</i>		8	10.7	
<i>Bacillus lentus</i>		8	10.7	
<i>Bacillus mycoides</i>		4	5.3	
<i>Bacillus alvei</i>		4	5.3	
<i>Bacillus polymyxa</i>		3	4	
<i>Bacillus circulans</i>		3	4	
<i>Micrococcus roseus</i>		3	4	
Total	10	75	100	

^a: The isolated amylase producing bacteria from soil. ^b: number of each isolated type from the total number of the positive isolated sample, ^c: percentage of each isolate, ^d: Average of colony-forming unit of amylase producing bacteria per ml of 100g soil samples (highest value- lowest value).

Table (2): Biochemical activities of amylase- producing bacterial isolates and its starch hydrolysis rate.

Isolate	Gram reaction	Motility	Catalase	Egg yolk lecithinase	Nitrate reduction	Vogas proskauer	Citrate utilization	Gelatin hydrolysis	Starch hydrolysis	Indole production
<i>Bacillus megaterium</i>	+	+	+	-	-	-	+	+	+	-
<i>Bacillus subtilis</i>	+	+	+	-	+	+	+	+	+	-
<i>Bacillus cereus</i>	+	+	+	+	+	+	+	-	+	-
<i>Bacillus thuringiensis</i>	+	+	+	+	-	+	+	-	+	-
<i>Bacillus lentus</i>	+	+	+	-	-	-	-	+	+	-
<i>Bacillus mycoides</i>	+	-	+	+	-	+	+	-	+	+
<i>Bacillus alvei</i>	+	+	+	-	-	+	-	+	+	+
<i>Bacillus polymyxa</i>	+	+	+	-	+	+	-	+	+	-
<i>Bacillus circulans</i>	+	+	+	-	+	-	-	+	+	-
<i>Micrococcus roseus</i>	+	+	+	-	+	-	+	-	+	-
Starch hydrolysis rate (mm) ^b										
	Halo zone (mm)			Diameter of colony (mm)				SHR		
<i>Bacillus megaterium</i>	16			3				5.33		
<i>Bacillus subtilis</i>	10			2				5.0		
<i>Bacillus cereus</i>	12			3				4.0		
<i>Bacillus thuringiensis</i>	17			3				5.67		
<i>Bacillus lentus</i>	14			4				3.5		
<i>Bacillus mycoides</i>	4			2				2.0		
<i>Bacillus alvei</i>	18			3				6.0		
<i>Bacillus polymyxa</i>	7			5				1.4		
<i>Bacillus circulans</i>	16			5				3.2		
<i>Micrococcus roseus</i>	10			5				2.0		

^a: Morphological and biochemical tests used for identification of the isolated bacteria. +: Positive, -: Negative, ^b: starch hydrolysis rate.

Table (3): Antibacterial activity of *Bacillus sp.* and purified amylase enzyme compared with different standard antibiotics.

Tested pathogens	<i>E. coli</i>	<i>Klebsiella pneumoniae</i>	<i>Acinetobacter baumannii</i>	<i>Pseudomonas aeruginosa</i>	<i>Staphylococcus aureus</i> (MRSA)
Antibiotic ^a /Isolates					
Chloramphenicol	S	R	S	I	I
Oxacillin	ND	ND	ND	ND	R
Vancomycin	ND	ND	ND	ND	R
Ampicillin- sulbactam	I	I	R	I	ND
Penicillin G	ND	ND	ND	ND	R
Erythromycin	ND	ND	ND	ND	I
Sulfamethoxazole-trimethoprim	R	R	R	R	I
Cefotaxime	R	R	R	R	R
Gentamycin	R	R	R	R	R
Meropenem	S	R	R	R	ND
Piperacillin	R	R	R	R	ND
Piperacillin-tazobactam	R	R	R	S	ND
Inhibition zone (mm) ^b					
<i>Bacillus megaterium</i>	21±1.5	26±1	36±1	24±1	31±1
<i>Bacillus subtilis</i>	12±1	18±2	21±1	15±1.5	20±2
<i>Bacillus cereus</i>	12±1.2	21±1	36±1	18±1	14±1.5
<i>Bacillus thuringiensis</i>	14±1.5	21±1	21±1	22±1	18±0.6
<i>Bacillus lentus</i>	22±1.6	22±1	24±0.6	32±1.5	31±3
<i>Bacillus mycoides</i>	NI	NI	NI	NI	NI
<i>Bacillus alvei</i>	34±1.5	21±1	39±1.5	29±2.5	48±2
<i>Bacillus polymyxa</i>	36±2.5	17±0.6	38±1	17±4	20±0.6
<i>Bacillus circulans</i>	21±1.5	23±1	39±1	32±1	32±2
<i>Micrococcus roseus</i>	NI	NI	NI	NI	NI
Inhibition zone (mm) ^c					
ABM	7.2±0.3	7.5±0	NI	NI	NI
ABS	7.3±0.3	7±0	NI	NI	NI
ABC	7±0.3	7.3±0.3	NI	NI	NI
ABT	7.5±0	7.2±0.3	NI	NI	NI
ABL	7.3±0	7.5±0	NI	NI	NI
ABA	7.5±0.5	7.3±0.3	NI	NI	NI

^a: Antimicrobial susceptibility of a group of standard antibiotics according to CLSI, 2017 against five human pathogenic strains as control. R= Resistant, S= sensitive, I= intermediate, ND= Not detected, ^b: antimicrobial activity of the isolated *Bacillus sp.*, NI= No inhibition, ^c: antimicrobial activity of purified amylase from some isolated *Bacillus sp.*, ABM = amylase purified from *Bacillus megaterium*, ABS amylase purified from *Bacillus subtilis*, ABC= amylase purified from purified *Bacillus cereus*, ABT= amylase purified from *Bacillus thuringiensis*, ABL= amylase purified from *Bacillus lentus*, ABA amylase purified from *Bacillus alvei*. Values expressed as mean± SD.

Table (4): Purification profile of amylase produced from different isolates of *Bacillus* sp.

Purification step ^a Isolates ^b	Crude		Ammonium sulfate		Dialysis		Sephadex G-200	
	EA (U/ml)	TA (U)	EA (U/ml)	TA (U)	EA (U/ml)	TA (U)	EA (U/ml)	TA (U)
<i>Bacillus megaterium</i>	33.15	6630	35.06	701.0	35.9	718	80.03	800
<i>Bacillus subtilis</i>	25.0	5000	32.0	640	35.0	700	76.0	760
<i>Bacillus cereus</i>	19.66	3932	23.08	461.0	25.12	502	55.9	559
<i>Bacillus thuringiensis</i>	39.45	7890	41.0	820	40.26	805	88.64	886
<i>Bacillus lentus</i>	13.9	2780	15.4	308	18.26	365	45.69	456.9
<i>Bacillus alvei</i>	50.2	10040	51.47	1029	29.56	591	96.02	960

^a: different purification steps of amylase purification, ^b: selected isolated *Bacillus* sp. for amylase purification according to SHR, EA: enzyme activity, TA: total activity

Fig. (1): Antagonistic efficacy of isolated *Bacillus sp.* from soil against some human pathogenic bacteria. (a) represent moderate inhibition, (b) represent the highest inhibition, (c) represents no inhibition (d) represent starch hydrolysis rate (SHR).




Fig. (2): Optimization and purification conditions of amylase enzyme from selected *Bacillus* sp.




Fig. (3): Antibiofilm activity of *Bacillus*-producing amylase-filtrate against some pathogenic bacteria after 48h treatment. Shown are *Bacillus* sp. filtrate, T1: *B. megaterium*, T2: *B. subtilis*, T3: *B. cereus*, T4: *B. thuringiensis*, T5: *B. lentus*, T6: *B. alvei*, T7: *B. polymyxa*, T8: *B. circulans*. The tested pathogenic bacteria are (a) *E. coli*, (b) *Klebsiella pneumoniae*, (c) *Acinetobacter baumannii*, (d) *Pseudomonas aeruginosa*, (e) *Staphylococcus aureus* (MRSA). Shown are the medians from at least eight independent measurements. The error bars indicate the interquartile range.




Fig. (4): Antibiofilm activity of *Bacillus*- purified amylase enzyme against some pathogenic bacteria after 48h treatment. Shown are *Bacillus* sp. filtrate, T1: *B. megaterium*, T2: *B. subtilis*, T3: *B. cereus*, T4: *B. thuringiensis*, T5: *B. lentus*, T6: *B. alvei*. The tested pathogenic bacteria are (a) *E. coli*, (b) *Klebsiella pneumoniae*, (c) *Acinetobacter baumannii*, (d) *Pseudomonas aeruginosa*, (e) *Staphylococcus aureus* (MRSA). Shown are the medians from at least eight independent measurements. The error bars indicate the interquartile range.

